The multicenter, phase 2, single-arm DESTINY-Breast01 study evaluated the efficacy and safety of T-DXd in HER2+ BC patients with unresectable metastatic disease who had previously received treatment with TDM-1. This evidence concerns the gene ERBB2 and breast cancer.